Ashley Kline

Ashley Kline serves as the Chief Commercial Officer at Palvella Therapeutics, a company dedicated to developing novel therapies for rare genetic skin diseases. Previously, Ashley held roles as a Senior Commercial Advisor and fractional Chief Commercial Officer at Tarsier Pharma, focusing on commercial and launch planning for an innovative medicine in late-stage development for eye disease. Experience includes consulting at Biotech Consulting, where Ashley partnered with biotech firms to optimize market potential for pipeline programs. As Head of the Global Biotech Business Unit at Dompé, Ashley led efforts to successfully launch Oxervate, exceeding growth forecasts and generating significant shareholder value. Earlier experience includes leading commercial strategy at Santen for a Phase 3 medicine targeting orphan eye disease. Educational credentials include an MBA from Northwestern University's Kellogg School of Management and a BA from the University of North Carolina at Chapel Hill.